Liquid biopsy can identify the resistance to targeted therapy in a timely manner, showing a higher coverage of tumor heterogeneity, more complex resistance patterns, and some new resistance mutation sites, such as EGFR p.V769M and KRAS p.A11V [91]. The gene discussed is EGFR; the disease is neoplasm.